Related Experiment Video
Updated: Jul 6, 2026
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
RNAi therapeutics: an update on delivery
Thu Nguyen1, Ellen M Menocal, Jens Harborth
1Harvard Medical School, Skip Ackerman Center for Molecular Therapeutics, Beth Israel Deaconess Medical Center, DANA 607, 330 Brookline Avenue, Boston, MA 02215, USA.
Current Opinion in Molecular Therapeutics
|April 4, 2008
Summary
RNA interference (RNAi) therapies show promise but face delivery challenges. This review covers 2005-2007 research on improving short interfering RNA (siRNA) delivery for in vivo applications and clinical trials.
Area of Science:
- Biotechnology
- Molecular Biology
- Medical Science
Background:
- RNA interference (RNAi) is a biological process utilizing short interfering RNAs (siRNAs) to target and degrade specific messenger RNA (mRNA).
- The high specificity and efficacy of RNAi present significant therapeutic potential in medicine.
- Challenges in siRNA stability and cellular uptake have historically limited RNAi-based therapeutic development.
Purpose of the Study:
- To review advancements in RNAi delivery methods published between 2005 and 2007.
- To focus on in vivo applications and clinical trials of RNAi delivery systems.
- To highlight the advantages and disadvantages of various RNAi delivery strategies.
Main Methods:
- Literature review of scientific publications from 2005-2007.
- Analysis of studies focusing on in vivo delivery of short interfering RNAs (siRNAs).
- Examination of clinical trial data related to RNAi therapeutics.
Main Results:
- Numerous methods for facilitating RNAi delivery in vivo have been developed.
- Each delivery method presents unique benefits and drawbacks.
- Progress has been made in addressing siRNA instability and inefficient cell membrane penetration.
Conclusions:
- Effective delivery remains a critical hurdle for RNAi-based therapeutics.
- Ongoing research focuses on optimizing delivery systems for clinical translation.
- The period 2005-2007 saw significant efforts in advancing RNAi delivery for therapeutic use.
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
02:22Regulated mRNA Transport
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing specific...
02:22Regulated mRNA Transport
In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing specific...